Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber, Ken Herrmann, Jérémie Calais, et al.
Journal of Nuclear Medicine (2017) Vol. 59, Iss. 3, pp. 469-478
Open Access | Times Cited: 478

Showing 1-25 of 478 citing articles:

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Wolfgang P. Fendler, Jérémie Calais, Matthias Eiber, et al.
JAMA Oncology (2019) Vol. 5, Iss. 6, pp. 856-856
Open Access | Times Cited: 631
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jérémie Calais, Francesco Ceci, Matthias Eiber, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 9, pp. 1286-1294
Open Access | Times Cited: 410
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Michael J. Morris, Steven P. Rowe, Michael A. Gorin, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 13, pp. 3674-3682
Open Access | Times Cited: 282
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Francesco Ceci, Daniela E. Oprea‐Lager, Louise Emmett, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 5, pp. 1626-1638
Open Access | Times Cited: 274
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
Thomas A. Hope, Matthias Eiber, Wesley R. Armstrong, et al.
JAMA Oncology (2021) Vol. 7, Iss. 11, pp. 1635-1635
Open Access | Times Cited: 248
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Wolfgang P. Fendler, Manuel Weber, Amir Iravani, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 24, pp. 7448-7454
Open Access | Times Cited: 239
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
Thomas A. Hope, Jeremy Goodman, Isabel E. Allen, et al.
Journal of Nuclear Medicine (2018) Vol. 60, Iss. 6, pp. 786-793
Open Access | Times Cited: 211
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Wolfgang P. Fendler, Matthias Eiber, Mohsen Beheshti, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 5, pp. 1466-1486
Open Access | Times Cited: 193
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jérémie Calais, Tristan Grogan, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 8, pp. 1115-1125
Open Access | Times Cited: 175
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Stefano Fanti, Karolien Goffin, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2020) Vol. 48, Iss. 2, pp. 469-476
Open Access | Times Cited: 169
A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer
Pieter De Visschere, Chloë Standaert, Jurgen J. Fütterer, et al.
European Urology Oncology (2018) Vol. 2, Iss. 1, pp. 47-76
Closed Access | Times Cited: 168
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
Andrea Farolfi, Letizia Calderoni, Francesco Mattana, et al.
Journal of Nuclear Medicine (2021) Vol. 62, Iss. 5, pp. 596-604
Open Access | Times Cited: 150
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Robert Seifert, Louise Emmett, Steven P. Rowe, et al.
European Urology (2023) Vol. 83, Iss. 5, pp. 405-412
Open Access | Times Cited: 144
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Edouard J. Trabulsi, R. Bryan Rumble, Hossein Jadvar, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 17, pp. 1963-1996
Open Access | Times Cited: 139
A role for microfluidic systems in precision medicine
José M. Ayuso, Marı́a Virumbrales-Muñoz, Joshua M. Lang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 130
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
Ute Hennrich, Matthias Eder
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 713-713
Open Access | Times Cited: 105
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Silke Gillessen, Alberto Bossi, Ian D. Davis, et al.
European Urology (2022) Vol. 83, Iss. 3, pp. 267-293
Open Access | Times Cited: 86
Radiotheranostics in oncology: Making precision medicine possible
Eric O. Aboagye, Tara Barwick, Uwe Haberkorn
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 3, pp. 255-274
Open Access | Times Cited: 69
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer
Andrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
Radiology (2023) Vol. 308, Iss. 1
Closed Access | Times Cited: 50
Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
Nancy Y. Lee, Eric J. Sherman, Heiko Schöder, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 8, pp. 940-950
Closed Access | Times Cited: 39
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J. Karpinski, Johannes Hüsing, Kevin Claaßen, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1188-1201
Open Access | Times Cited: 20
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Martin Bakht, Himisha Beltran
Nature Reviews Urology (2024)
Closed Access | Times Cited: 16
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
Bernhard Grubmüller, Pascal Baltzer, Sabrina Hartenbach, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 24, pp. 6300-6307
Open Access | Times Cited: 138
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Bernhard Grubmüller, Daniela Senn, Gero Kramer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2018) Vol. 46, Iss. 5, pp. 1063-1072
Open Access | Times Cited: 126
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
Nat Lenzo, Danielle Meyrick, J. Harvey Turner
Diagnostics (2018) Vol. 8, Iss. 1, pp. 16-16
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top